Company news

Iovance Biotherapeutics, Inc. news in 2022

Iovance Biotherapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma

November 17, 2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 9, 2022

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates

November 2, 2022

Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy

October 9, 2022

Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

August 24, 2022

Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates

August 3, 2022

Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors

June 12, 2022

Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma

May 25, 2022

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 19, 2022

Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates

May 4, 2022

Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma

April 4, 2022

Iovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)

March 14, 2022

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates

February 23, 2022

Iovance Biotherapeutics Announces Raj K. Puri, M.D., Ph.D. to Join Leadership Team

January 9, 2022

Calls in 2022

Decks in 2022